Mepolizumab

美泊利单抗

Report date: 2026/05/26 20:00:28
First In Class

Base Information

Drug NameMepolizumab
Drug Alias Name美泊利珠单抗MepolizumabumMepolizamab美泊珠单抗Bosatria +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-5 inhibitors
TargetsInterleukin-5
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Chronic UrticariaDermatitis, Atopic +[16] 
Global Approved IndicationsEosinophilic Granulomatosis With PolyangiitisAsthma
Approved Indications in ChinaEosinophilic Granulomatosis With Polyangiitis
Original Approved Country/TerritoryUnited States
Original Approved Date2015/11/04
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Trading Services LtdGlaxosmithkline PlcGlaxosmithkline (Ireland) Ltd +[11] 
Inactive CompaniesThe Brigham and Women's HospitalJohannes Gutenberg-University MainzGlaxosmithkline Manufacturing Spa +[5] 
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Chronic UrticariaHypereosinophilic Syndrome +[11] 
Inactive IndicationsDermatitis, AtopicAngioedemaFasciitis +[5] 

Other Information

ATC CodeR03DX09
Related LinksWikipediaDrugBankKEGG